FDA Approves New Dose Of RISPERDAL® CONSTA® For Schizophrenia Treatment

The U.S. Food and Drug Administration (FDA) approved a 12.5 mg dose of RISPERDAL® CONSTA® [(risperidone) Long-Acting Injection] for the treatment of schizophrenia within specific patient populations, including those with renal and hepatic impairment. [click link for full article]
From: www.medicalnewstoday.com